Diagnosis of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome in the setting of erosive or lichenoid mucocutaneous disease
Indirect Immunofluorescence Assay (IFA)
Basement Membrane Antibodies
Bullous Lupus Erythematosus
Bullous Pemphigoid
Cicatricial Pemphigoid
Circulating IgG Basement Membrane Zone Antibody
Circulating Intercellular Ab Study
Epidermal Cell Surface Antibody
Epidermal Fluorescence Antibody
Epidermolysis Bullosa Acquisita
Epithelial Antibody
Herpes gestationis
IMF - Epidermal Fluorescent Ab
Indirect Immunofluorescence
Intercellular Substance Antibody
Lupus Erythematosus (LE)
Paraneoplastic Pemphigus (PNP)
Pemphigoid
Pemphigus
Skin Basement Membrane Antibodies
Split-Skin Assay
PAMS- Paraneoplastic autoimmune multiorgan syndrome
Serum
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 2 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
0.5 mL
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 14 days | |
Frozen | 30 days | ||
Ambient | 14 days |
Diagnosis of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome in the setting of erosive or lichenoid mucocutaneous disease
Paraneoplastic pemphigus (PNP) (also paraneoplastic autoimmune multiorgan syndrome [PAMS] to denote the systemic nature of the syndrome) is an autoimmune mucocutaneous blistering disease affecting adults or, rarely, children that generally heralds the presence of an underlying malignancy.
PNP/PAMS can be defined and identified by a combination of the following features:
1. Painful stomatitis and a polymorphous cutaneous eruption with lesions that may be blistering, lichenoid, erythema multiforme-like, or morbilliform
2. Variable histopathologic findings, including acantholysis, lichenoid, or interface change
3. Variable direct immunofluorescence findings from a perilesional biopsy, often demonstrating deposition of IgG and complement in the epidermal intercellular spaces, granular/linear complement deposition along the epidermal basement membrane zone, or a lichenoid tissue reaction
4. Indirect immunofluorescence evidence of cell surface deposition on primate esophagus or rat bladder epithelium
5. Enzyme-linked immunosorbent assay evidence of serum autoantibodies against desmogleins 1 or 3 and, possibly, against bullous pemphigoid 180 and 230 antigens
The incidence of the disease is unknown, but it is less common than pemphigus vulgaris or foliaceus. Clinical features of the disease can mimic those seen in a drug reaction, erythema multiforme, Stevens-Johnson syndrome, pemphigus, lichen planus, or toxic epidermal necrolysis.
In the majority of cases, PNP/PAMS is associated with non-Hodgkin lymphoma, chronic lymphocytic leukemia, thymoma, or Castleman disease. A serious complication includes bronchiolitis obliterans, which may lead to respiratory failure.
Negative
In the appropriate clinical setting, a positive result can support a diagnosis of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome (PNP/PAMS). However, correlation with clinical features, histopathologic findings, results of serum studies (such as indirect immunofluorescence on primate esophagus substrate and enzyme-linked immunosorbent assay for Dsg1/3) is required for a final diagnosis.
As the test is not entirely sensitive, a negative test result does not exclude the possibility of PNP/PAMS.
Test results must be interpreted in the patient's individual clinical context.
1. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323(25):1729-1735. doi:10.1056/NEJM199012203232503
2. Anhalt GJ, Aris-Abdo L, Bonitz P, Labib RS. Antigen specificity of paraneoplastic pemphigus: predictive value of diagnostic techniques based on the study of 17 patients and 135 control subjects. J Invest Dermatol. 1992(4);98:580. Abstract 172
3. Liu AY, Valenzuela R, Helm TN, Camisa C, Melton AL, Bergfeld WF. Indirect immunofluorescence on rat bladder transitional epithelium: a test with high specificity for paraneoplastic pemphigus. J Am Acad Dermatol. 1993;28(5 Pt 1):696-699. doi: 10.1016/0190-9622(93)70095-b
4. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol. 1993;129(7):883-886
5. Montagnon CM, Tolkachjov SN, Murrell DF, et al. Intraepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. J Am Acad Dermatol. 2021;84(6): 1507-1519. doi:10.1016/j.jaad.2020.11.075
6. Montagnon CM, Lehman JS, Murrell DF, et al. Intraepithelial autoimmune bullous dermatoses: disease activity assessment and therapy. J Am Acad Dermatol. 2021;84(6);1523-1537. doi:10.1016/j.jaad.2021.02.073
Commercially-prepared sections of rat bladder (substrate) are overlaid with patient’s serum; incubated, covered with fluorescein-conjugated IgG antiserum, and interpreted using fluorescent microscopy.(Unpublished Mayo method)
Wednesday through Friday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
86255
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
PNPAB | Paraneoplastic Pemphigus, IgG Ab, S | 93233-5 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
61881 | Paraneoplastic Pemphigus, IgG Ab, S | 93233-5 |